Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

Vistagen’s repeat-dose anxiety nasal spray can’t beat placebo in mid-stage study

Vistagen’s repeat-dose anxiety nasal spray can’t beat placebo in mid-stage study

Published

on

The Phase 2 study was small and was not designed to establish the statistical difference between Vistagen’s drug candidate and placebo, according to Vistagen. The biotech plans to meet with the FDA to determine a registrational path for the asset.​ ​Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Replimune to ride wave of physician support to launch advanced melanoma therapy

Published

on

Analysts expect Replimune’s newly approved Tudriqev to reach $1.3 billion in peak sales in 2035.

Continue Reading

Uncategorized

‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit

Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.

Read More

Published

on

Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.

Read More

Continue Reading

Uncategorized

2026 Q2 Job Market Report: Job postings keep rising as fewer companies cut employees

Published

on

Job postings increase and competition dips, according to BioSpace data.

Continue Reading
Advertisement

Trending